Equities research analysts expect Haemonetics Corporation (NYSE:HAE) to report earnings per share (EPS) of $0.42 for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Haemonetics Corporation’s earnings. The lowest EPS estimate is $0.40 and the highest is $0.46. Haemonetics Corporation posted earnings of $0.46 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 8.7%. The company is expected to report its next earnings report on Monday, November 6th.

According to Zacks, analysts expect that Haemonetics Corporation will report full year earnings of $1.61 per share for the current financial year, with EPS estimates ranging from $1.59 to $1.65. For the next financial year, analysts anticipate that the company will report earnings of $1.80 per share, with EPS estimates ranging from $1.70 to $1.86. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Haemonetics Corporation.

Haemonetics Corporation (NYSE:HAE) last released its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The business had revenue of $211 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same period last year, the business earned $0.25 earnings per share. The firm’s revenue was up .5% on a year-over-year basis.

A number of research analysts have recently weighed in on HAE shares. BidaskClub cut shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. Jefferies Group LLC reissued a “buy” rating and set a $48.00 price objective on shares of Haemonetics Corporation in a research note on Thursday, July 27th. JMP Securities raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research note on Thursday, July 13th. Zacks Investment Research raised shares of Haemonetics Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $40.71.

Haemonetics Corporation (HAE) traded down 0.35% during trading on Friday, hitting $42.29. 241,610 shares of the company traded hands. The stock has a 50-day moving average price of $41.69 and a 200-day moving average price of $40.64. Haemonetics Corporation has a 12-month low of $32.76 and a 12-month high of $43.77. The firm has a market capitalization of $2.22 billion, a P/E ratio of 549.22 and a beta of 0.89.

Several institutional investors and hedge funds have recently made changes to their positions in HAE. Teachers Advisors LLC boosted its holdings in shares of Haemonetics Corporation by 2.5% in the 4th quarter. Teachers Advisors LLC now owns 85,025 shares of the medical instruments supplier’s stock valued at $3,418,000 after purchasing an additional 2,081 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Haemonetics Corporation by 7.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 73,789 shares of the medical instruments supplier’s stock valued at $2,993,000 after acquiring an additional 4,986 shares during the period. American Century Companies Inc. raised its stake in shares of Haemonetics Corporation by 0.9% in the 1st quarter. American Century Companies Inc. now owns 45,846 shares of the medical instruments supplier’s stock valued at $1,860,000 after acquiring an additional 405 shares during the period. US Bancorp DE raised its stake in shares of Haemonetics Corporation by 4.3% in the 1st quarter. US Bancorp DE now owns 22,013 shares of the medical instruments supplier’s stock valued at $893,000 after acquiring an additional 917 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Haemonetics Corporation by 5.0% in the 1st quarter. Bank of New York Mellon Corp now owns 756,590 shares of the medical instruments supplier’s stock valued at $30,697,000 after acquiring an additional 35,852 shares during the period.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Haemonetics Corporation (HAE) Will Post Earnings of $0.42 Per Share” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/09/analysts-anticipate-haemonetics-corporation-hae-will-post-earnings-of-0-42-per-share.html.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get a free copy of the Zacks research report on Haemonetics Corporation (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.